FDA approves generic Camptosar in chemotherapy
Teva Pharmaceutical Industries has received FDA approval for the Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer’s chemotherapy agent, Camptosar(R) (Irinotecan Hydrochloride) Injection. Camptosar’s patent expired last month and the drug had annual sales of about $556 million in the U.S. in the twelve months ended December 31, 2007. The other companies that have received approval to launch the generic version of Pfizer’s chemotherapy agent are Actavis and APP Pharmaceuticals.
- Orchid receives FDA nod for generic Kytril
- Mylan receives FDA nod for generic Plendil
- Teva gets FDA nod for generic Fosamax
- FDA confirms safety and efficacy of generic Wellbutrin
